Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk

Journal of the National Cancer Institute

Volumn 94, Issue 1, 2002, Pages 32-38

  Schildkraut, Joellen M ^a,d   Calingaert, Brian ^a   Marchbanks, Polly A ^c   Moorman, Patricia G ^a   Rodriguez, Gustavo C ^b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETYNODIOL DIACETATE PLUS MESTRANOL; GESTAGEN; MESTRANOL PLUS NORETHISTERONE; MESTRANOL PLUS NORETYNODREL; ORAL CONTRACEPTIVE AGENT; PROVEST; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCULATION; CANCER RISK; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; EPIDEMIOLOGY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVULATION INHIBITION; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

EID: 0037005946     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.1.32     Document Type: Article

References (41)

1. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women
2. Ovarian cancer
3. A case-control study of oral contraceptive use and invasive ovarian cancer
4. Incidence of ovarian cancer in relation to the use of oral contraceptives
5. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development
6. Events of reproductive life and the incidence of epithelial ovarian cancer
7. Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group
8. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer
9. Too many rodent carcinogens: Mitogenesis increases mutagenesis
10. Increased cell division as a cause of human cancer
11. Determinants of ovarian cancer risk. I. Reproductive experiences and family history
12. An epidemiologic study of the relationship of reproductive experience to cancer of the ovary
13. An epidemiologic study of epithelial carcinoma of the ovary
14. Risk factors for epithelial ovarian cancer in Italy
15. Epithelial ovarian cancer and combination oral contraceptives
16. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group
17. Ovarian tumors of the hen
18. The impact of parity, infertility and treatment with fertility drugs on the risk of ovarian cancer
19. Pregnancy recency and risk of ovarian cancer
20. Reproductive factors and incidence of epithelial ovarian cancer: A Norwegian prospective study
21. Parity, age at first childbirth, and risk of ovarian cancer
22. Effect of progestin on the ovarian epithelium of macaques: Cancer prevention through apoptosis?
23. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis
24. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation
25. N-(4-Hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid
26. Retinoids in cancer chemoprevention
27. Antiproliferative potency of structurally distinct dietary flavonoids on human colon cancer cells
28. Sulfone metabolite of sulindac inhibits mammary carcinogenesis
29. Cancer chemoprevention and therapy by monoterpenes
30. Chemoprevention by S-adenosyl-L-methionine of rat liver carcinogenesis initiated by 1,2-dimethylhydrazine and promoted by orotic acid
31. Chemoprevention of cancer by organoselenium compounds
32. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone
33. High-dose and low-dose combined oral contraceptives: Protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives
34. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE Study Group. Steroid Hormones and Reproductions
35. The evaluation of the data collection process for a multicenter, population-based, case-control design
36. Differences in risk factors for epithelial ovarian cancer by histologic type
37. Risk factors for epithelial ovarian tumours of borderline malignancy
38. Hormones
39. Oral contraceptives in the United States: Trends in content and potency
40. Pharmacokinetics of mestranol in man in relation to its oestrogenic activity